MAXIBOLIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Maxibolin, and what generic alternatives are available?
Maxibolin is a drug marketed by Organon Usa Inc and is included in two NDAs.
The generic ingredient in MAXIBOLIN is ethylestrenol. Additional details are available on the ethylestrenol profile page.
US Patents and Regulatory Information for MAXIBOLIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon Usa Inc | MAXIBOLIN | ethylestrenol | ELIXIR;ORAL | 014006-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Organon Usa Inc | MAXIBOLIN | ethylestrenol | TABLET;ORAL | 014005-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
